


PHARMACEUTICAL 2019

iBio Inc. Rank 174 of 371







PHARMACEUTICAL 2019

iBio Inc. Rank 174 of 371



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 183% points. The greatest weakness of iBio Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -136%, being 195% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	16,285
Cost of Goods Sold	0
Intangible Assets	1,620
Liabilities, Current	2,035
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	24,884
Other Net Income	-1,881
Property and Equipment	25,152
Research and Development	3,986
Revenues	444
Selling, General and Administrative Expense	10,685

Output Variable	Value in 1000 USD
Assets	43,083
Liabilities	26,919
Expenses	14,671
Stockholders Equity	16,164
Net Income	-16,108
Comprehensive Net Income	-16,108
Economic Capital Ratio	-136%